Filana Therapeutics, Inc. (FLNA)
NASDAQ: FLNA · Real-Time Price · USD
1.560
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.568
+0.008 (0.53%)
After-hours: Apr 28, 2026, 7:48 PM EDT
Company Description
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer’s disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026.
The company was incorporated in 1998 and is based in Austin, Texas.
Filana Therapeutics, Inc.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Richard Barry |
Contact Details
Address: 6801 N. Capital of Texas Highway, Building 1 Austin, Texas 78731 United States | |
| Phone | 512 501 2444 |
| Website | filanatx.com |
Stock Details
| Ticker Symbol | FLNA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001069530 |
| CUSIP Number | 14817C107 |
| ISIN Number | US14817C1071 |
| Employer ID | 91-1911336 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Jon Barry | Chief Executive Officer, President and Director |
| Eric J. Schoen | Chief Financial Officer |
| R. Christopher Cook J.D. | Chief Operating and Legal Officer |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology |
| Michael Zamloot | Senior Vice President of Technical Operations |
| Freda Nassif | Chief Business Officer and Chief Commercial Officer |
| Jaren Landen | Chief Clinical Development Officer |
| Dr. Angelique Bordey Ph.D. | Senior Vice President of Neuroscience |
| Jack Moore Ph.D. | Senior Vice President of Clinical Development |
| Dr. Joseph Hulihan M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 10-K | Annual Report |
| Mar 12, 2026 | 8-K | Current Report |
| Mar 10, 2026 | 8-K | Current Report |
| Feb 19, 2026 | 8-K | Current Report |
| Dec 23, 2025 | 8-K | Current Report |
| Dec 22, 2025 | 8-K/A | [Amend] Current report |
| Dec 18, 2025 | 8-K | Current Report |